ATX 3.33% 6.2¢ amplia therapeutics limited

Ann: Amplia Initiates Multiple Dose Study of AMP945, page-2

  1. 340 Posts.
    lightbulb Created with Sketch. 74
    Great work. The clear objective of making timely progress is reassuring, as is the absence of any adverse reactions (the endpoint of a phase 1 trail).
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.